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Humoral factors and extracellular matrix are critical
co-regulators of smooth muscle cell (SMC) migration and
proliferation. We reported previously that focal adhesion
kinase (FAK)-related non-kinase (FRNK) is expressed se-
lectively in SMC and can inhibit platelet-derived growth
factor BB homodimer (PDGF-BB)-induced proliferation
and migration of SMC by attenuating FAK activity. The
goal of the current studies was to identify the mechanism
by which FAK/FRNK regulates SMC growth and migra-
tion in response to diverse mitogenic signals. Transient
overexpression of FRNK in SMC attenuated autophos-
phorylation of FAK at Tyr-397, reduced Src family-de-
pendent tyrosine phosphorylation of FAK at Tyr-576, Tyr-
577, and Tyr-881, and reduced phosphorylation of the
FAK/Src substrates Cas and paxillin. However, FRNK ex-
pression did not alter the magnitude or dynamics of ERK
activation induced by PDGF-BB or angiotensin II. In-
stead, FRNK expression markedly attenuated PDGF-BB-,
angiotensin II-, and integrin-stimulated Rac1 activity and
attenuates downstream signaling to JNK. Importantly,
constitutively active Rac1 rescued the proliferation de-
fects in FRNK expressing cells. Based on these observa-
tions, we hypothesize that FAK activation is required to
integrate integrin signals with those from receptor tyro-
sine kinases and G protein-coupled receptors through
downstream activation of Rac1 and that in SMC, FRNK
may control proliferation and migration by buffering FAK-
dependent Rac1 activation.
Smooth muscle cell (SMC)1 proliferation is certainly impor-
tant during vascular development, but it is clear that increased
SMC proliferation and migration are important contributors to
the pathogenesis of several important cardiovascular disease
states including atherosclerosis, restenosis, and hypertension.
A large number of extrinsic cues (growth factors, extracellular
matrix, cell-cell interactions, etc.) have been identified that
regulate SMC growth and migration (1, 2). However, the pre-
cise cellular signaling mechanisms involved are not completely
understood, and very little is known about how (or if) these
signaling pathways are integrated.
The majority of soluble SMC mitogens can be broadly divided
into two groups, activators of receptor tyrosine kinases (i.e.
platelet-derived growth factor BB homodimer (PDGF-BB), ba-
sic fibroblast growth factor, insulin-like growth factor-1 (IGF-
1), and activators of G protein-coupled receptors (i.e. angioten-
sin II (Ang II), thrombin, endothelin-1 (ET-1); see Ref. 2). A
large body of evidence indicates that members of both groups
activate (to varying degrees) the Ras/Raf/MEK/ERK and PI3K/
Rac/PAK/JNK kinase cascades, phospholipase C, and protein
kinase C signaling pathways, among others (1). Interestingly,
it is becoming clear that the mitogenic responses elicited by
many of these factors are dependent upon extracellular matrix
(ECM)/integrin interactions. For example, when cultured fibro-
blasts are held in suspension, PDGF-, epidermal growth fac-
tor-, and lysophosphatidic acid-stimulated ERK activity is
markedly reduced compared with cells plated on fibronectin
(3, 4).
Integrin-mediated activation of the non-receptor tyrosine ki-
nase, focal adhesion kinase (FAK), is a critical step in integrin
signaling and may be important for growth factor signaling, as
well. In support of this idea, several mitogens (including
PDGF-BB, Ang II, IGF-1, and ET-1) stimulate FAK tyrosine
phosphorylation in an adhesion-dependent manner (5–8). In
addition, Renshaw et al. (9) have shown that integrin augmen-
tation of growth factor-mediated signaling to ERK2 appears to
be dependent upon FAK activation, because the inhibition of
mitogen-activated protein kinase activation observed in sus-
pended cells can be rescued by overexpression of activated
FAK. Furthermore, integrin-mediated autophosphorylation of
FAK on Tyr-397 leads to recruitment and activation of Src and
PI3K and subsequent downstream activation of Ras/ERK or
Rac/JNK cascades (10, 11).
Interestingly, our laboratory showed recently that FAK ap-
pears to be regulated in a unique fashion in SMC. We reported
that the noncatalytic C-terminal domain of FAK, termed FAK
related non-kinase (FRNK), is selectively expressed in SMC
with very high levels found in the large arterioles. FRNK
transcription results from the utilization of an alternative start
site within the FAK gene, and FRNK expression is independ-
ently regulated by a distinct promoter embedded within FAK
intronic sequences (12, 13). Interestingly, whereas FAK protein
levels remain relatively constant, FRNK protein levels in vivo
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are dynamically regulated with increased FRNK expression in
the neonatal period and from 2 to 3 weeks following balloon
injury. This pattern of expression correlates with the attenua-
tion of SMC proliferation that is known to occur under these
circumstances, suggesting that FRNK may be an important
regulator of SMC growth (2). In support of this idea, we have
shown that overexpression of GFP-FRNK in rat aortic SMC
completely prevented the PDGF-BB-induced increase in
[3H]thymidine incorporation and significantly inhibited the mi-
togenic effects of serum. In addition, GFP-FRNK also signifi-
cantly inhibited fibronectin-dependent SMC migration toward
PDGF-BB (12). Taken together these data suggest that FRNK
acts as an endogenous inhibitor of FAK activity and that its
expression in vivo may act to buffer FAK-dependent prolifera-
tive and migratory signals.
In this report we sought to identify the mechanism by which
FRNK attenuates growth factor and adhesion signaling in
SMC. Our data indicate that in contrast to other cell types,
FAK/FRNK signaling does not modify agonist-stimulated ERK
activity in SMC. Instead, our data reveal that in SMC, Rac1
activation may be a key convergence point in growth factor-
and FAK-dependent integrin-regulated cell proliferation.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—The 4G10 phosphotyrosine-specific anti-
body, an anti-human FAK antibody, and the Rac1 antibody were pur-
chased from Upstate Biotechnology, Inc. The phosphotyrosine-specific
anti-FAK antibodies (Tyr-397, Tyr-576, Tyr-577, and Tyr-861) were
purchased from BioSource International. Texas Red-conjugated phal-
loidin was purchased from Molecular Probes. The phosphospecific and
immobilized phospho-p44/42 mitogen-activated protein kinase antibody
was purchased from Cell Signaling, along with the phospho-stress-
activated protein kinase/JNK (Thr-183/Tyr-185) and phospho-ELK-1
antibodies. CAS was detected using a mixture of two polyclonal anti-
bodies generated against the C-terminal domain of CAS (CAS-F and
CAS-P; provided by Dr. Amy Bouton, University of Virginia) (14). The
monoclonal ERK1/2 antibody (1B3B9) was generously provided by Dr.
Michael Weber (University of Virginia). The anti-FLAG (M5) antibody,
Ang II, and fibronectin were purchased from Sigma, and PDBF-BB was
purchased from Calbiochem.
Adenovirus Production and Expression Constructs—The GFP and
GFP-tagged FRNK viruses (replication-defective 5 adenovirus) were
plaque-purified by cesium chloride gradients as described previously
(12). The cDNA construct encoding an N-terminal DsRed-conjugated
L61Rac1 was generated by cloning L61Rac1 into the 5 BamHI and 3
EcoRI restriction sites in the pDsRed2-CI vector (Clontech).
Cell Culture, Infection, Transfection, and Agonist Treatment—Rat
aortic SMC were obtained from 8-week rat thoracic aortas by enzymatic
digestion as described previously (15). Cells were used from passages
7–21 and were maintained in Dulbecco’s modified Eagle’s medium-F-12
(1:1) plus 10% fetal bovine serum and 1% penicillin-streptomycin.
For adenoviral infection, cells were incubated in serum containing
medium with either GFP or GFP-FRNK (MOI 10) for 12–15 h prior to
treatment. In some experiments, cells were serum-starved for 4 h
followed by treatments with PDGF-BB or Ang II for the times indicated.
For the adhesion suspension experiments, cells were trypsinized, neu-
tralized in soybean trypsin inhibitor (1 mg/ml in PBS), collected by
centrifugation, and resuspended in serum-free Dulbecco’s modified Ea-
gle’s medium-F-12. Cells were held in suspension or plated on fibronec-
tin-coated (40 g/ml) dishes for the times indicated. In some experi-
ments, SMC were transfected using Gene Jammer transfection reagent
(Stratagene) following the manufacturer’s instructions.
Immunocytochemistry—SMC were plated on Lab Tek II chamber
slides (5,000 cells/cm2; Nalgene) and infected with virus, as described
above. Cells were serum-starved for 4 h (Dulbecco’s modified Eagle’s
medium-F-12, 1% penicillin-streptomycin) and then dosed with 20
ng/ml PDGF-BB for 45 min. Slides were then washed three times with
PBS (calcium- and magnesium-free) and fixed in 4% paraformaldehyde
in PBS for 20 min. Following an additional three washes in PBS, slides
were permeabilized for 3 min with 4% Triton X-100 in PBS. Detergent
was removed by washing three times with PBS and then slides were
blocked with blocking solution (5% goat serum, 2% bovine serum albu-
min in PBS) for 30 min. Cells were incubated for 1 h with Texas Red
phalloidin in PBS (1:1000) to visualize filamentous actin. All steps were
performed at room temperature.
BrdUrd and WST-1 Proliferation Assays—To detect BrdUrd incor-
poration, SMC plated on Lab Tek II chamber slides, as described above,
were transfected with 0.7 g of pDsRedC1 vector (DsV) or pDsRedC1-
tagged RacL61 (DsRacL61) using Gene Jammer transfection reagent.
48 h following transfection, cells were infected with GFP or GFRNK
adenoviruses for 15 h. Cells were serum-starved as described above and
then treated with either 10% fetal bovine serum or PDGF-BB (30 ng/ml)
overnight. Cells were then incubated with 1/1000 dilution of BrdUrd
labeling reagent (Roche) for 1 h at 37 °C. Slides were washed three
times for 5 min with PBS and then fixed with ethanol (50 mM glycine,
70% ethanol, pH 2.0) in the dark at 20 °C for 20 min. BrdUrd detec-
tion reagent was used following the manufacturers instructions, fol-
lowed by a 30-min incubation at 37 °C with a cascade blue-conjugated
secondary antibody (1:1000; Molecular Probes). Slides were washed and
mounted with coverslips, and BrdUrd-positive nuclei were visualized by
indirect fluorescence microscopy. For the WST-1 experiments, SMC
were plated in 96-well culture dishes (2,000 cells/well) and treated as
described above, with the exception that the WST-1 tetrazolium salt
(Roche Applied Science) was added to the culture for 2 h to monitor cell
proliferation as per the manufacturer’s instructions. After this incuba-
tion period the production of formazan dye was quantitated using a
spectrophotometer (450 nm).
Immunoprecipitation and Western Blotting—SMC were lysed in
modified radioimmune precipitation assay buffer (50 mM Hepes, 0.15 M
NaCl, 2 mM EDTA, 0.1% Nonidet P-40, 0.05% sodium deoxycholate, pH
7.2) containing 1 mM Na3VO4, 40 mM NaF, 10 mM Na2 pyrophosphate,
100 M leupeptin, 1 mM 4-(2-aminoethyl)benzenesulfonyl fluoride hy-
drochloride, 0.02 mg/ml soybean trypsin inhibitor, and 0.05 trypsin
inhibitory units/ml aprotinin. CAS and paxillin were immunoprecipi-
tated by incubation of 1 mg of cell extract with 5 g of the appropriate
antibody for 2 h at 4 °C, followed by a 1-h incubation with protein
A-Sepharose-conjugated beads (Amersham Biosciences). For paxillin
immunoprecipitations, the beads were pre-coupled rabbit anti-mouse
Ab (10 g/ml; Jackson Laboratories). The immune complexes were
collected by centrifugation and washed three times with radioimmune
precipitation assay buffer and two times with Tris-buffered saline (0.2
M NaCl, 50 mM Tris-HCl, pH 7.4). Proteins were boiled in sample buffer
and resolved on a 10% SDS-PAGE and transferred to nitrocellulose.
Western blots were performed using the appropriate antibodies at a
1/1000 dilution (except anti-ERK, 1B3B9, which was used at 1:10,000).
Blots were washed in Tris-buffered saline plus 0.05% Triton-X, followed
by incubation with either horseradish peroxidase-conjugated protein
A-Sepharose (Amersham Biosciences) or horseradish peroxidase-conju-
gated rabbit anti-mouse antibody (Amersham Biosciences) at a 1/2000
dilution. Blots were visualized after incubation with chemilumines-
cence reagents (ECL; Amersham Biosciences).
Kinase Activity—Kinase activity was measured by using a p44/p42
MAPK assay kit (Cell Signaling), following the manufacturers protocol.
In brief, 250 g of lysate from PDGF-BB or vehicle treated SMC was
incubated with 15 g of provided immobilized phospho-p44/p42 MAPK
antibody, and complexes were rotated overnight at 4 °C. Immune com-
plexes were collected by centrifugation and washed three times with
provided 1 lysis buffer and resuspended in provided 1 kinase buffer
containing 200 M ATP and 2 g of ELK-1 fusion protein. The reaction
was incubated at 30 °C for 30 min and terminated by the addition of 3
SDS sample buffer. Sample proteins were electrophoresed on an 11%
SDS-PAGE gel, transferred to a nitrocellulose membrane, incubated
with phophos-ELK-1 antibody, and processed as described above.
GST Pull Down Assay—GST-Pak (amino acid 1–290 of Pak1) was
purified from bacterial lysates using glutathione-agarose beads (Amer-
sham Biosciences) as described previously (16). GFP- or GFRNK-in-
fected SMC were serum-starved and treated with PDGF-BB or Ang II
as described above. Cells were lysed in Buffer A (50 mM Tris, pH 7.6,
500 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% Triton X-100, 0.5 mM
MgCl2, plus 100 M leupeptin, 1 mM 4-(2-aminoethyl)benzenesulfonyl
fluoride hydrochloride, and 0.05 trypsin inhibitory units/ml aprotinin)
and cleared by centrifugation for 10 min at 14000 rpm at 4 °C (17). 500
g of lysate was combined with 30 g of GST-PAK, and samples were
rotated at 4 °C for 30 min. The complexes were pelleted by centrifuga-
tion and washed two times in Buffer B (50 mM Tris, pH 7.6, 150 mM
NaCl, 1%Triton X-100, 0.5 mM MgCl2, plus 100 M leupeptin, 1 mM
AEBSF, and 0.05 trypsin inhibitory units/ml). Samples were boiled in
SDS-PAGE buffer, electrophoresed (15% SDS-PAGE gel), and trans-
ferred to polyvinylidene difluoride (Bio-Rad). Western blotting was
performed using an anti-Rac1 primary antibody as described above.
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RESULTS
We reported previously that overexpression of GFP-FRNK in
cultured aortic SMCs by adenoviral gene transfer resulted in a
modest increase in FRNK protein effectively inducing an exog-
enous FRNK to endogenous FAK ratio of around 3:1. This
FRNK:FAK ratio compares favorably with endogenous ratios
observed in neonatal vessels and is sufficient to inhibit both
FAK activity and PDGF-BB-stimulated proliferation and mi-
gration. To begin to dissect the signaling pathways altered by
FRNK expression in SMC, we first examined the effect of
FRNK overexpression on total cellular phosphotyrosine levels.
In adherent cultures of SMC, three major tyrosine phosphoryl-
ated bands were attenuated in GFRNK in comparison with
GFP-infected or uninfected control cells (Fig. 1A). The 125-kDa
protein is probably FAK because FAK co-migrates with this
band, and FRNK overexpression in SMC inhibits autophospho-
rylation of Tyr-397 as reported previously (12). The use of
additional phosphospecific antibodies demonstrated that
FRNK overexpression in SMC also inhibited phosphorylation
of the major Src-dependent phosphorylation sites in FAK
namely pY556, pY557, and pY861 (Fig. 1B). The tyrosine-
phosphorylated proteins migrating at 130 and 70 kDa likely
represent the FAK binding partners p130Cas and paxillin (Fig.
1C).
Because proliferation and migration of SMC in response to
PDGF-BB are at least partially dependent on ERK activation
(18–20), and because ERK activation has been reported to be
dependent on FAK/p130Cas interactions (21), we tested
whether overexpression of GFP-FRNK could attenuate mito-
gen-stimulated ERK activity. Surprisingly, dose-dependent
stimulation of ERK by PDGF-BB was not altered by overex-
pression of GFP-FRNK (Fig. 2A, top panel) even though PDGF-
BB-stimulated FAK activation (in the same lysates) was clearly
attenuated (Fig. 2A, middle panel).
Because the time course of ERK1/2 activation may also reg-
ulate cell cycle progression, (22, 23) we examined whether
FRNK might alter the kinetics of PDGF-BB-stimulated ERK
activity. As shown in Fig. 2, B and C, FRNK expression did not
alter the kinetics of PDGF-BB-induced ERK activation at time
points ranging from 1 min to 3 h. In addition, we observed no
significant difference in the ability of ERK to phosphorylate
ELK-1 as assessed by an immune-complex kinase assay that
measures direct phosphorylation of a GST-ELK fusion protein
(Fig. 2C). These data likely indicate that in SMC, FRNK inhib-
its PDGF-BB-stimulated migration and proliferation in an
ERK-independent fashion.
Other major signaling pathways known to regulate both
proliferation and migration include activation of the small GT-
Pases of the Rho family. Interestingly, Rac1 has been shown
previously (24, 25) to be activated both by PDGF receptors and
following engagement of certain integrins. We used a well
defined assay to examine Rac1 activation in SMC using a
GST-PAK1 fusion protein to precipitate active (GTP-bound)
but not inactive (GDP-bound) Rac1. As shown in Fig. 3A, this
GST fusion protein effectively precipitated activated L61Rac
but not inactive N17Rac when these constructs were overex-
pressed in COS-7 cells. Using this assay, we have shown that
PDGF-BB induced a rapid transient activation of Rac1 in SMC.
PDGF stimulated an approximate 2–3-fold increase in Rac1
activity, which peaked between 1 and 3 min following stimu-
lation (Fig. 3B, left panel). As shown in Fig. 3B, right panel,
overexpression of GFP-FRNK slightly inhibited basal activity
and markedly attenuated PDGF-stimulated Rac1 activity in
SMC. In addition, activation of JNK (a kinase known to be
downstream of Rac1 activation) was also attenuated in the
FIG. 1. FRNK inhibits FAK, p130CAS, and paxillin phosphoryl-
ation in SMC. Rat aortic SMC were infected with GFP or GFRNK
adenovirus for 12 h. Extracts (100 g) were analyzed by SDS-PAGE and
immunoblotting using a generic anti-phosphotyrosine antibody (4G10)
(panel A), an antibody to total FAK, or phosphorylation-specific anti-
bodies to pY397, pY576, pY577, and pY861 of FAK (panel B). C, paxillin
(PAX) or p130Cas (CAS) were immunoprecipitated (IP) from the GFP-
or GFP-FRNK-infected cell extracts as described under “Experimental
Procedures” followed by immunoblotting with anti-phosphotyrosine an-
tibody (4G10) and the appropriate antibody for loading controls.
FIG. 2. FRNK expression does not alter dose- or time-depend-
ent activation of ERK by PDGF-BB in SMC. Rat aortic SMC were
infected with GFP or GFP-FRNK adenovirus (multiplicity of infection,
10) for 12 h. Cells were transferred to serum-free medium and incu-
bated for 4 h. Cells were treated with PDGF-BB (0–30 ng/ml) for 10 min
(panel A) or with PDGF-BB (20 ng/ml) for various times as indicated
(panel B). Lysates were electrophoresed, and Western analysis was
performed using anti-ERK, or anti-phosphospecific ERK and FAK
(pY397) Ab. Panel C, ERK was immunoprecipitated (IP) from cell ly-
sates with an anti-ERK1/2 antibody, and immune complexes were
washed and incubated with 2 g of purified GST-ELK immobilized on
glutathione beads in a kinase buffer containing 10 mM MgCl2 and 200
M ATP for 30 min at 30 °C. Immune complexes were then electrophore-
sed, and Western analysis was performed using a phosphorylation-
specific ELK-1 antibody. The plus sign () indicates a positive control
whereby 20 ng of active ERK was added to the reaction. Control blots
indicated that FRNK expression significantly attenuated FAK phospho-
tyrosine as assessed by Western blotting with an anti pY397 antibody in
each experiment. Data are representative of at least three separate
experiments.
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GFP-FRNK expressing cells (Fig. 3C). Because Rac1 activation
stimulates the formation of distinct actin-rich lamellipodia, an
important event during cell motility (24, 26, 27), we examined
whether FRNK expression in SMC might alter this process in
PDGF-BB-stimulated SMC. Indeed, in GFP-infected cells,
PDGF-BB stimulated a reorganization of actin filaments and a
resultant ruffled morphology (note the dissolution of stress
fibers and formation of actin bundles around the periphery of
the PDGF-BB-stimulated cells; see Fig. 3D, top panels). In
contrast, PDGF treatment of GFP-FRNK-infected cells did not
result in noticeable changes in actin rearrangements (Fig. 3D,
bottom panels). Taken together, these data indicate that FRNK
expression attenuates the activation of Rac1 and Rac1-depend-
ent signals in SMC.
To determine whether inhibition of Rac1 was the sole deter-
minant for the proliferative defects induced by FRNK, we ex-
amined the ability of activated Rac1 to rescue PDGF-BB-stim-
ulated proliferation in FRNK overexpressing cells. To this end,
SMC were transfected with either DsV or DsRacL61 prior to
infection with GFP and GFP-FRNK adenoviruses. Following
serum starvation, cells were treated with PDGF and analyzed
for their capacity to incorporate BrdUrd. Consistent with our
previous report, FRNK overexpression attenuated PDGF-stim-
ulated BrdUrd incorporation by 40% to a level comparable
with cells in serum-free media (p  0.05 compared with GFP-
infected cells; see Fig. 4). Importantly, although Rac1 alone had
little effect on BrdUrd incorporation in GFP expressing cells,
overexpression of constitutively active L61Rac1 efficiently res-
cued the effects of FRNK on cell proliferation (p  0.01 com-
pared with FRNK  DsV). Control experiments indicated that
similar amounts of FRNK were expressed under both condi-
tions (Fig. 4, upper panel). These data indicate that Rac1 acts
downstream of FAK/FRNK to control SMC proliferation.
To determine whether inhibition of Rac1 activity might be a
general mechanism by which FRNK attenuates SMC growth,
we examined the capacity of FRNK to inhibit Ang II-mediated
signal transduction. We found that overexpression of FRNK
also inhibits Ang II-stimulated cell growth reducing the prolif-
erative index by 77  12% after a 24-h treatment as assessed
colorimetrically by monitoring cleavage of the tetrazolium salt,
WST-1. These data corroborate studies reported elsewhere (28)
and suggest that FRNK can inhibit proliferative signals in-
duced by G protein-coupled receptors, as well as receptor tyro-
sine kinases. Because Ang II has also been shown to stimulate
Rac1 activity in SMC (29) and other cell types, we examined
whether this effect might also be altered by FRNK. Indeed, as
shown in Fig. 5A, Ang II stimulated a rapid transient increase
in Rac1 activity in SMC, and this effect was attenuated by
ectopic expression of GFP-FRNK. As shown in Fig. 5, B and C,
neither the kinetics of Ang II-stimulated ERK activation nor
the concentrations of Ang II required for maximal ERK activa-
tion were significantly altered by overexpression of GFP-FRNK
in SMC. Control experiments indicated that Ang II does stim-
ulate FAK activity and that this activity is blocked by overex-
pression of FRNK. Thus, FRNK appears to attenuate both Ang
II- and PDGF-BB-dependent mitogenic signaling without ef-
fects on ERK activity.
As noted above signaling through many SMC mitogens is
dependent on ECM, but the precise mechanisms involved in
this regulation have not been clearly defined. In certain cell
types, fibronectin-binding integrins have been shown to con-
tribute to the activation of Rac1 (30). Thus, we examined
FIG. 3. FRNK expression inhibits PDGF-BB-stimulated Rac1 activation and membrane ruffling in SMC. A, COS cells were transfected
with FLAG-tagged active (L61) Rac1 or dominant-negative (N17) Rac1 for 48 h. Lysates were prepared and incubated with 30 g of purified
GST-PAK1 immobilized on glutathione beads for 30 min. Beads were washed, boiled in sample buffer, electrophoresed, and Western blotted using
an anti-FLAG Ab. PD indicates the Rac1 precipitated with GST-PAK, and L indicates a 10% loading control. B, rat aortic SMC were infected with
GFP or GFP-FRNK adenovirus (multiplicity of infection, 10) for 12 h. Cells were transferred to serum-free medium and incubated for 4 h. Cells
were treated with 20 ng/ml PDGF-BB for the indicated times. Lysates were incubated with 30 g of purified GST-PAK for 30 min, complexes were
washed, and Western blotting was performed using an anti-Rac1 Ab. The bottom panels represent a 10% loading control of total Rac1 in the lysates.
C, rat aortic SMC were infected and treated with PDGF-BB (20 ng/ml) as described above for times indicated. Lysates were electrophoresed, and
Western analysis was performed using phosphorylation-specific anti-JNK, anti-ERK, or anti-FAK (pY397) antibodies. The blot was stripped and
re-probed using an anti-ERK Ab to serve as a loading control. D, rat aortic SMC were infected with GFP or GFP-FRNK adenovirus and
serum-starved as described above. Cells were treated with 20 ng/ml PDGF-BB for 45 min. Cells were fixed and stained with Texas Red-conjugated
phalloidin to visualize filamentous actin as described under “Experimental Procedures.” The ruffled phenotype was observed in 87% of GFP-
infected cells compared with 22% of FRNK-infected cells (187/215 and 46/205 cells, respectively). Data shown are representative of at least three
separate experiments.
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whether plating SMC on fibronectin would stimulate the
activation of Rac1 in SMC and if so, whether expression of
FRNK might alter integrin-dependent Rac1 activation. As
shown in Fig. 6, plating SMC on fibronectin stimulated a
transient activation of Rac1 that peaked at 1 h, and overex-
pression of FRNK attenuated this response at each time
point (Fig. 6). In contrast, overexpression of FRNK had little
effect on fibronectin-stimulated ERK activity. These data
indicate that FRNK attenuates FAK-dependent activation of
Rac1 in response to PDGF-BB, Ang II, and integrins. Based
on these observations, we hypothesize that Rac1 activation
may be a key convergence point in growth factor and integrin-
regulated cell proliferation and migration in SMC and that
FRNK may act to regulate signaling through diverse path-
ways at this level (see Fig. 7).
DISCUSSION
Numerous studies have implicated a role for the non-recep-
tor tyrosine kinase, FAK, in the regulation of migration and
proliferation. FAK is strongly activated by integrin-, growth
factor receptor-, and G protein-coupled receptor engagement
and thus may serve to integrate downstream signals from a
variety of agonists; however, the precise mechanisms by which
FAK regulates signaling from these diverse pathways have not
been clearly defined (11). In this report, we studied the conver-
gence of growth factor and integrin signaling through FAK in
the regulation of vascular SMC proliferation. As we reported
previously (12, 31, 32), FAK activity appears to be regulated in
a unique fashion in SMC whereby autonomous expression of
the C-terminal domain of FAK (termed FRNK) can act as an
endogenous inhibitor of FAK signaling. In recent studies, we
have shown the following: 1) that FRNK is expressed selec-
tively in SMC with high levels observed in the vasculature; 2)
that FRNK expression is regulated during development and
following vascular injury; and 3) that ectopic expression of
FRNK in cultured SMC blocked PDGF-BB-stimulated migra-
tion and proliferation (12). These data indicate that FRNK
expression may impart tight regulation on FAK-dependent
ECM-mediated signaling events in SMC. Here we report that
expression of FRNK in SMC blocks mitogenic signaling from
diverse factors by attenuating FAK-dependent co-activation of
the Rac/JNK but not the Ras/ERK pathway.
Ras/ERK and Rac/JNK are two of the main pathways known
to be key regulators of cell proliferation and migration. Cell
adhesion to extracellular matrix regulates Ras/ERK signaling
in many cell types, and studies have clearly shown that maxi-
mal growth factor signaling to ERK is anchorage-dependent
(33). Several pieces of evidence highlight a possible role for
FAK activation in ERK-dependent growth regulation. First,
several mitogens (including PDGF-BB, Ang II, phenylephrine,
IGF-1, and ET-1) stimulate FAK tyrosine phosphorylation in
an adhesion-dependent manner (5–8). Second, at least two
pathways have been defined by which FAK can activate ERK
activity. One pathway involves adhesion-dependent tyrosine
phosphorylation of FAK at residue 925, which directs Src ho-
FIG. 4. L61Rac1 expression overcomes inhibitory effect of FRNK on proliferation. SMC were transfected with DsV or a DsRed fusion
protein containing the constitutively active form of Rac1 (DsRacL61). 48 h after transfection, cells were infected with GFP or GFP-FRNK virus as
described above. Cells were serum-starved for 4 h and then dosed overnight with either 30 ng/ml PDGF-BB or vehicle control. Cells were labeled
with BrdUrd, fixed, and stained for BrdUrd using a cascade blue-conjugated secondary antibody as described under “Experimental Procedures.”
The BrdUrd labeling index for cells positive for GFP and DsRed was determined, and data are presented as the percentage of cells labeled positive
in the PDGF-BB-stimulated versus unstimulated wells. The graph represents means  S.E. of three independent experiments in which a total of
180–350 cells were counted for each condition. The percentage of BrdUrd-positive cells in the unstimulated GFP-FRNK control group was 18.2 
1.9%. Levels of GFP-FRNK were comparable in DsV and DsRacL61 expressing cells (see upper panel).
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mology 2-mediated binding to the adapter protein Grb2, and
recruitment of the GTP exchange factor Sos followed by subse-
quent activation of the Ras/Raf/MEK/ERK pathway (34, 35),
and a separate pathway involves the adhesion-dependent as-
sociation of the adapter protein CAS with FAK, which can
facilitate ERK signaling through the adapter proteins Nck and
Sos and subsequent activation of the Ras/Raf/MEK/ERK path-
way (21). Finally, overexpression of FAK can rescue growth
factor-induced ERK activation in non-adherent cells whereas
inhibition of FAK function can attenuate activation of ERK in
adherent cells (9, 36). Indeed, we reported previously (37) that
adenoviral infection of GFP-FRNK inhibits phenylephrine-
stimulated ERK activation in isolated cardiomyocytes.
In contrast, we have clearly shown in this report that FRNK
expression attenuates FAK signaling in primary cultured SMC
(in which FRNK is expressed endogenously) without effect on
the time- or dose-dependent activation of ERK by both strong
(PDGF-BB) or weak agonists (Ang II). Instead, the effects of
FRNK on mitogen- and ECM-induced proliferation were medi-
ated by inhibition of Rac1/JNK, a conclusion strongly sup-
ported by our results demonstrating that L61 Rac1 was suffi-
cient to rescue the FRNK inhibitable component of PDGF-BB-
stimulated cell proliferation. Our results do differ somewhat
from a previous report in which stable transfection of FRNK
into smooth muscle-like cells reduced PDGF-stimulated ERK
activity at low but not high concentrations of PDGF (38). The
apparent discrepancies between these results may be because
of their use of smooth muscle cell lines immortalized by large T
antigen as opposed to primary SMC cultures. Thus, we propose
that the mechanisms by which FAK regulates adhesion-de-
pendent growth factor signaling may be cell type-specific. In-
deed, previous work (39) has shown that in keratinocytes,
integrin-dependent ERK activation appears to proceed through
SHC- but not FAK-dependent signals. Perhaps similar FAK-
independent ERK signaling pathways are utilized in SMC.
Although most of our data indicate that the effects of FRNK are
mediated by inhibition of FAK, we cannot rule out the possi-
bility that FRNK might regulate signaling in a FAK-independ-
ent fashion in SMC.
Our results do not completely exclude the possibility that
FAK/FRNK may play a role in regulating ERK signaling in
SMC in vivo. It is still possible that weak ERK activation
FIG. 5. FRNK expression attenuates
Ang II-stimulated Rac1 but not ERK
activity in SMC. Rat aortic SMC were
infected with GFP or GFP-FRNK adeno-
virus (multiplicity of infection, 10) for
12 h. Cells were transferred to serum-free
medium and incubated for 4 h. Cells were
treated with Ang II for various times
(panels A and B) or with various concen-
trations (panel C). A, lysates were incu-
bated with 30 g of purified GST-PAK as
described above. Western blotting was
performed using an anti-Rac1 Ab. The
bottom panels represent a 10% loading
control of total Rac1 in the lysate. B and
C, lysates were electrophoresed, and
Western analysis was performed using an
anti-ERK or anti-phosphospecific ERK
Ab. Control blots indicated that FRNK
expression significantly attenuated FAK
pY397 in each experiment. Data in panel
A are representative of three separate ex-
periments, and data in panels B and C are
representative of at least four separate
experiments.
FIG. 6. FRNK expression blocks FN-stimulated Rac1 activity
in SMC. SMC were infected with GFP or GFP-FRNK as described
above. Cells were trypsinized, neutralized in soybean trypsin inhibitor,
pooled, and either held in suspension (S) or plated on fibronectin (FN)
for the times indicated. Cells were lysed and incubated with 30 g of
purified GST-PAK as described above. Western blotting was performed
using an anti-Rac1 Ab. The middle panel represent a 10% loading
control of total Rac1 in the lysate. Levels of active ERK in lysates were
assessed using an anti-phosphospecific ERK Ab (bottom panel). Data
are representative of three separate experiments.
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induced by limiting amounts of mitogens in the vessel wall may
be more susceptible to the effects of FRNK. It is also possible
that examination of total ERK activity may not be represent-
ative of the relevant functional activity of this enzyme in the
cell. For instance, active ERK localizes to focal adhesions, as
well as the nucleus, suggesting that targeting of this kinase
may direct specificity toward downstream targets (40, 41).
Thus, FRNK may attenuate localization of active ERK, which
could be masked in experiments designed to measure total
activity in cell lysates. Interestingly, adhesion to the ECM is
required for efficient accumulation of active ERK in the nu-
cleus, and recent studies (40, 42) point to a role for Rac1 in
mediating this process. Therefore, although FRNK might not
affect ERK activation per se, it could affect downstream ERK
signaling secondary to its effect on Rac1 activation. Studies to
examine this possibility are currently underway.
Our data suggest that in SMC, Rac1 activation may be a key
convergence point in growth factor- and integrin-regulated cell
proliferation, because FRNK expression attenuated integrin-,
Ang II-, and PDGF-BB-stimulated Rac1 activation and down-
stream signaling. Activation of the small GTPase Rac1 elicits
membrane ruffling and lamellipodia formation upon growth
factor stimulation, and this modification of cell morphology is
required for cell spreading and migration (24, 26, 27). In addi-
tion, activation of Rac1 is required for cyclin D1 expression and
concomitant cell cycle progression (43, 44). Rac1, like other low
molecular GTPases, is a molecular switch that cycles between
the active GTP- and inactive GDP-bound states and is regu-
lated by numerous proteins that facilitate this process. The
exchange of GDP for GTP is accelerated by guanosine nucleo-
tide exchange factors, whereas GTPase-activating proteins in-
crease the intrinsic rate of GTP hydrolysis. In the GTP-bound
form, Rac1 interacts with and activates a number of effector
molecules that have been implicated in regulating proliferation
and migration including serine/threonine protein kinases, lipid
kinases, and actin binding/scaffolding proteins (45, 46). We
have shown that FRNK expression attenuates PDGF-BB-me-
diated activation of JNK, a stress-activated protein kinase
downstream of Rac1 signaling known to control cell prolifera-
tion. In addition, we showed that the proliferative defect in
FRNK expressing cells was completely rescued by active
RacL61. Taken together, these data provide strong evidence
that Rac1 is co-regulated by FAK-dependent integrin and
growth factor signaling.
Recent studies corroborate the suggestion that activation of
the Rac1 GTPase may be the critical convergence point for
mitogen- and integrin-dependent growth and migration in cer-
tain cell types. In endothelial cells, mitogens stimulate robust
ERK activity when cells are attached to either fibronectin or
laminin but only stimulate proliferation when the cells are
plated on fibronectin. This effect was correlated to the ability of
fibronectin (but not laminin) to support mitogen-stimulated
Rac1 activity, indicating a role for Rac1 in adhesion-dependent
growth responses (30). Two other reports show that  integrins
are both necessary and sufficient for adhesion dependent Rac1
activation. Hirsch et al. (47) showed that fibroblasts derived
FIG. 7. Schematic summarizing mitogenic signaling pathways that regulate SMC growth and migration. A variety of agonists that
regulate SMC growth and migration are known to regulate Rac/JNK and Ras/ERK signaling. We hypothesize that FAK activation is required to
integrate signals from integrins, receptor tyrosine kinases, and G protein-coupled receptors leading to the downstream activation of Rac1. In SMC,
FRNK may control proliferation and migration by buffering this FAK-dependent response.
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from mice that express a mutated 1 integrin display defective
activation of FAK, Rac1, and JNK but not ERK and are im-
paired in G1-S cell cycle progression. In addition, Berrier et al.
(48) showed that clustering 1 and 3 integrin tails on the
surface of non-adherent cells activates Rac1 activity.
FAK activates a number of signaling molecules that might
contribute to integrin-dependent Rac1 (and downstream JNK)
activation. Evidence suggests that FAK-dependent signaling
through CAS, paxillin, or PI3K can lead to activation of Rac1 by
several different mechanisms. Integrin-mediated activation of
Rac1 could proceed through a FAK/(CAS or paxillin)/Crk/
DOCK 180 pathway. Indeed, dominant interfering mutants of
the Src homology 2/Src homology 3 adapter protein Crk, the
adapter/exchange factor DOCK 180, or Rac1 each attenuate
Cas- or paxillin-stimulated cell migration (49–52). Recently, a
more direct paradigm has been suggested whereby FAK-de-
pendent activation of paxillin could lead to focal adhesion re-
cruitment and activation of the putative Cdc42/Rac guanine
nucleotide exchange proteins PIX/COOL (3, 30, 53). Alterna-
tively, activation of Rac1 could proceed through a FAK/PI3K/
Sos pathway. PI3K associates with Tyr-397 of FAK upon
integrin ligation and one of its catalytic products,
phosphatidylinositol triphosphate, binds to and activates the
PH domain-containing guanine nucleotide exchange factor,
Sos, which can activate both Rac1 and Ras (53, 54). In endo-
thelial cells fibronectin-stimulated Rac1 activity is dependent
on FAK/PI3K/Sos signaling (30); however, recent data using
Src-transformed fibroblasts suggest that a FAK/CAS/DOCK
180 pathway might be utilized (55). Whether the pathways
leading from FAK to Rac/JNK are redundant or differentially
regulated in a cell type-specific fashion are important questions
that remain to be addressed.
ECM is a critical component of the medial layers of the vessel
wall that serves to both maintain vascular integrity and to
regulate vascular development and remodeling. Results from
genetic deletion of various ECM components, integrin recep-
tors, and FAK each result in extraembryonic and embryonic
vessel defects leading to lethality at approximately day 8.5–10
of mouse development supporting a role for adhesion signaling
in the regulation of growth and migration of vascular SMC
(56–59). FAK is co-activated by integrins and autocrine factors,
and its activation is necessary for proliferation and migration
in a number of cell types (11). We have shown that FAK activity
may be regulated in a unique fashion in SMC, because FRNK,
a dominant inhibitory form of FAK, is selectively expressed in
these cells. FRNK overexpression inhibits both Ang II- and
PDGF-BB-stimulated migration and proliferation, effects that
are likely due to the ability of FRNK to block Rac1 activation.
Interestingly, several SMC mitogens have been linked to Rac1
activation in either SMC (i.e. Ang II) or other cell types (i.e.
PDGF, ET-1, IGF-1, fibroblast growth factor), and proliferative
signals induced by these agonists are attenuated by overex-
pression of a dominant interfering mutant for Rac1 (29, 60–
64). Thus, it is tempting to speculate that enhanced signaling
through FAK to Rac1 is permissive for SMC growth during
development and for the phenotypic reversion of SMC to a more
proliferative state following vascular injury and that expres-
sion of FRNK might hold these processes in check.
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